RAPID-WATER-FLOW试验的原理与设计:放射性标记灌注用水的PET显像评估心肌血流反应以识别冠状动脉疾病
RAPID-WATER-FLOW是一项开放标签、多中心、前瞻性研究,计划在北美和欧洲约10个中心纳入约215例疑似冠状动脉疾病(CAD)患者,评估15O-水PET心肌灌注显像检测限流性狭窄的诊断灵敏度与特异度。真值标准为有创冠状动脉造影(ICA)联合血流储备分数(FFR)或瞬时无波形比率(iFR),或冠状动脉CT血管造影(CCTA)排除CAD。主要终点要求灵敏度和特异度的95%置信区间下限均大于60%。
要点
- 研究评估15O-水PET心肌灌注显像诊断限流性CAD的灵敏度与特异度,真值标准为ICA联合FFR/iFR或CCTA。
- 计划纳入约215例疑似CAD患者,在北美和欧洲约10个中心开展。
- 主要终点要求灵敏度和特异度的95%置信区间下限均超过60%。
核心结论
- RAPID-WATER-FLOW研究是一项前瞻性、多中心研究,旨在确定15O-水PET与ICA联合FFR/iFR或CCTA相比诊断CAD的灵敏度与特异度。
研究设计与样本
- 开放标签、多中心、前瞻性研究,计划在北美和欧洲约10个研究中心纳入约215例疑似CAD患者。
- 研究将使用自动化系统生产、给药和注射15O-水,并采用为15O-水PET采集开发的定量分析平台。
- 所有入组个体在指数PET扫描后随访不良事件和严重不良事件至多32小时。
- 研究把握度>90%(单侧检验,α=0.025),用于检验15O-水PET的灵敏度和特异度均>60%的假设。
- 临床试验注册号:ClinicalTrials.gov(NCT05134012)。
主要发现
- 原文为研究设计论文,尚未报告研究结果。
关键数值与推荐
- 主要终点为15O-水PET的诊断灵敏度和特异度,真值标准为ICA联合FFR或iFR判定限流性狭窄,或CCTA排除CAD。
- 灵敏度和特异度均需满足95%置信区间下限超过60%才视为阳性,与既往注册研究一致。
- 亚组分析包括女性、肥胖、糖尿病个体以及多支血管病变患者的诊断灵敏度、特异度和准确度评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of this study was to determine the diagnostic performance of 15O-water positron emission tomography (PET) myocardial perfusion imaging to detect coronary artery disease (CAD) using the truth-standard of invasive coronary angiography (ICA) with fractional flow reserve (FFR) or instantaneous wave-Free Ratio (iFR) or coronary computed tomography angiogram (CCTA). BACKGROUND: 15O-water has a very high first-pass extraction that allows accurate quantification of myocardial blood flow and detection of flow-limiting CAD. However, the need for an on-site cyclotron and lack of automated production at the point of care and relatively complex image analysis protocol has limited its clinical use to date. METHODS: The RAPID WATER FLOW study is an open-label, multicenter, prospective investigation of the accuracy of 15O-water PET to detect obstructive angiographic and physiologically significant stenosis in patients with suspected CAD. The study will include the use of an automated system for producing, dosing, and injecting 15O-water and enrolling approximately 215 individuals with suspected CAD at approximately 10 study sites in North America and Europe. The primary endpoint of the study is the diagnostic sensitivity and specificity of the 15O-water PET study using the truth-standard of ICA with FFR or iFR to determine flow-limiting stenosis, or CCTA to rule out CAD and incorporating a quantitative analytic platform developed for the 15O-water PET acquisitions. Sensitivity and specificity are to be considered positive if the lower bound of the 95% confidence interval is superior to the threshold of 60% for both, consistent with prior registration studies. Subgroup analyses include assessments of diagnostic sensitivity, specificity, and accuracy in female, obese, and diabetic individuals, as well as in those with multivessel disease. All enrolled individuals will be followed for adverse and serious adverse events for up to 32 hours after the index PET scan. The study will have >90% power (one-sided test, α = 0.025) to test the hypothesis that sensitivity and specificity of 15O-water PET are both >60%. CONCLUSIONS: The RAPID WATER FLOW study is a prospective, multicenter study to determine the diagnostic sensitivity and specificity of 15O-water PET as compared to ICA with FFR/iFR or CCTA. This study will introduce several novel aspects to imaging registration studies, including a more relevant truth standard incorporating invasive physiologic indexes, coronary CTA to qualify normal individuals for eligibility, and a more quantitative approach to image analysis than has been done in prior pivotal studies. CLINICAL TRIAL REGISTRATION INFORMATION: Clinical-Trials.gov (#NCT05134012).
引用
- Di Carli MF, Gormsen LC, Chareonthaitawee P, et al. Rationale and design of the RAPID-WATER-FLOW trial: Radiolabeled perfusion to identify coronary artery disease using water to evaluate responses of myocardial FLOW. J Nucl Cardiol. 2023. PMID: 38215598. doi:10.1016/j.nuclcard.2023.101779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。